Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about the study, please email [email protected] or call 312-355-5112.

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigator: Michael Abern, MD

Translate »